Literature DB >> 31985749

Implications of Abnormal Exercise Electrocardiography With Normal Stress Echocardiography.

Melissa A Daubert1,2, Joseph Sivak3, Allison Dunning2, Pamela S Douglas1,2, Brian Coyne1, Tracy Y Wang1,2, Daniel B Mark1,2, Eric J Velazquez4.   

Abstract

Importance: Patients with abnormal (positive) exercise electrocardiography, but normal stress echocardiography (+ECG/-Echo) are commonly encountered in clinical practice; however, the prognostic significance of this discordant result is unclear. Objective: To determine whether patients with +ECG/-Echo have a higher rate of adverse clinical events and a poorer prognosis than patients with negative exercise ECG and normal stress Echo imaging (-ECG/-Echo). Design, Setting, and Participants: Between January 1, 2000, and February 28, 2014, a total of 47 944 consecutive patients without known coronary artery disease who underwent exercise stress Echo at Duke University Medical Center were evaluated for inclusion in this observational cohort study. Data analysis was conducted from January 1, 2000, to December 31, 2016. Interventions/Exposures: Patients were categorized as having -ECG/-Echo, +ECG/-Echo, or +Echo (-ECG/+Echo and +ECG/+Echo). Main Outcomes and Measures: The primary outcome was a composite end point of death, myocardial infarction, hospitalization for unstable angina, and coronary revascularization. Secondary outcomes included individual adverse events and downstream testing.
Results: After excluding submaximal tests and nondiagnostic ECG or stress imaging results, 15 077 patients (mean [SD] age, 52 [13] years; 6228 [41.3%] men) were classified by stress test results. Of these, 12 893 patients (85.5%) had -ECG/-Echo, 1286 patients (8.5%) had +ECG/-Echo, and 898 patients (6.0%) had +Echo. Through a median follow-up of 7.3 (interquartile range, 4.4-10.0) years, the composite end point occurred in 794 patients with -ECG/-Echo (8.5%), 142 patients with +ECG/-Echo (14.6%), and 297 patients with +Echo (37.4%). Death occurred in 425 patients with -ECG/-Echo (4.8%), 50 patients with +ECG/-Echo (5.9%), and 70 patients with +Echo (11.2%). Myocardial infarction occurred in 195 patients with -ECG/-Echo (2.2%), 31 patients with +ECG/-Echo (3.6%), and 59 patients with +Echo (8.7%). The addition of stress ECG findings to clinical and exercise data yielded incremental prognostic value. Patients with -ECG/-Echo imaging results had the least downstream testing (2.3%), followed by +ECG/-Echo (12.8%), and +Echo (33.6%) (P < .001). Conclusions and Relevance: The presence of +ECG results with normal stress Echo imaging may identify a population of patients who are at slightly increased risk for adverse cardiac events, which was not previously recognized. Further study is needed to determine whether these patients will benefit from intensification of medical management.

Entities:  

Mesh:

Year:  2020        PMID: 31985749      PMCID: PMC6990669          DOI: 10.1001/jamainternmed.2019.6958

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  27 in total

1.  Optimal non-invasive imaging test selection for the diagnosis of ischaemic heart disease.

Authors:  Christopher B Fordyce; Pamela S Douglas
Journal:  Heart       Date:  2016-01-29       Impact factor: 5.994

Review 2.  Exercise echocardiography.

Authors:  T Ryan; H Feigenbaum
Journal:  Am J Cardiol       Date:  1992-06-18       Impact factor: 2.778

3.  2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Authors:  Stephan D Fihn; Julius M Gardin; Jonathan Abrams; Kathleen Berra; James C Blankenship; Apostolos P Dallas; Pamela S Douglas; Joanne M Foody; Thomas C Gerber; Alan L Hinderliter; Spencer B King; Paul D Kligfield; Harlan M Krumholz; Raymond Y K Kwong; Michael J Lim; Jane A Linderbaum; Michael J Mack; Mark A Munger; Richard L Prager; Joseph F Sabik; Leslee J Shaw; Joanna D Sikkema; Craig R Smith; Sidney C Smith; John A Spertus; Sankey V Williams
Journal:  J Am Coll Cardiol       Date:  2012-11-19       Impact factor: 24.094

4.  Long-term prognosis of patients with a normal exercise echocardiogram and clinical suspicion of myocardial ischemia.

Authors:  G Ismail; E Lo; M Sada; R D Conant; S M Shapiro; L E Ginzton
Journal:  Am J Cardiol       Date:  1995-05-01       Impact factor: 2.778

5.  Prediction of mortality by exercise echocardiography: a strategy for combination with the duke treadmill score.

Authors:  T H Marwick; C Case; C Vasey; S Allen; L Short; J D Thomas
Journal:  Circulation       Date:  2001-05-29       Impact factor: 29.690

6.  Outcome after normal exercise echocardiography and predictors of subsequent cardiac events: follow-up of 1,325 patients.

Authors:  R B McCully; V L Roger; D W Mahoney; B L Karon; J K Oh; F A Miller; J B Seward; P A Pellikka
Journal:  J Am Coll Cardiol       Date:  1998-01       Impact factor: 24.094

7.  Standardized guidelines for the interpretation of dobutamine echocardiography reduce interinstitutional variance in interpretation.

Authors:  R Hoffmann; H Lethen; T Marwick; R Rambaldi; P Fioretti; A Pingitore; E Picano; T Buck; R Erbel; F A Flachskampf; P Hanrath
Journal:  Am J Cardiol       Date:  1998-12-15       Impact factor: 2.778

8.  Long-term prognostic value of exercise echocardiography compared with exercise 201Tl, ECG, and clinical variables in patients evaluated for coronary artery disease.

Authors:  L I Olmos; H Dakik; R Gordon; J K Dunn; M S Verani; M A Quiñones; W A Zoghbi
Journal:  Circulation       Date:  1998-12-15       Impact factor: 29.690

9.  Long term favorable prognostic value of negative treadmill echocardiogram in the setting of abnormal treadmill electrocardiogram: a 95 month median duration follow-up study.

Authors:  Mouaz Al-Mallah; Fadi Alqaisi; Abdulilah Arafeh; Rachid Lakhdar; Rania Al-Tamsheh; Karthik Ananthasubramaniam
Journal:  J Am Soc Echocardiogr       Date:  2008-07-23       Impact factor: 5.251

10.  Prediction of mortality and major cardiac events by exercise echocardiography in patients with normal exercise electrocardiographic testing.

Authors:  Alberto Bouzas-Mosquera; Jesús Peteiro; Nemesio Alvarez-García; Francisco J Broullón; Victor X Mosquera; Lourdes García-Bueno; Luis Ferro; Alfonso Castro-Beiras
Journal:  J Am Coll Cardiol       Date:  2009-05-26       Impact factor: 24.094

View more
  4 in total

1.  Role of Exercise Treadmill Testing in the Assessment of Coronary Microvascular Disease.

Authors:  Diana M Lopez; Sanjay Divakaran; Ankur Gupta; Navkaranbir S Bajaj; Michael T Osborne; Wunan Zhou; Jon Hainer; Courtney F Bibbo; Hicham Skali; Sharmila Dorbala; Viviany R Taqueti; Ron Blankstein; Marcelo F Di Carli
Journal:  JACC Cardiovasc Imaging       Date:  2021-08-18

Review 2.  Stress electrocardiography testing in coronary artery disease: Is it time for its swan song or to redefine its role in the modern era ?

Authors:  Gnanasundaram Ananthasubramaniam; Karthikeyan Ananthasubramaniam
Journal:  Indian Heart J       Date:  2022-02-12

Review 3.  Gender-Related Differences in Chest Pain Syndromes in the Frontiers in CV Medicine Special Issue: Sex & Gender in CV Medicine.

Authors:  Puja K Mehta; Janet Wei; Chrisandra Shufelt; Odayme Quesada; Leslee Shaw; C Noel Bairey Merz
Journal:  Front Cardiovasc Med       Date:  2021-11-17

4.  Relationship of Stress Test Findings to Anatomic or Functional Extent of Coronary Artery Disease Assessed by Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve.

Authors:  Demetrios Doukas; Sorcha Allen; Amy Wozniak; Siri Kunchakarra; Rina Verma; Jessica Marot; John J Lopez; Koen Nieman; Gianluca Pontone; Jonathon Leipsic; Jeroen Bax; Mark G Rabbat
Journal:  Biomed Res Int       Date:  2021-02-24       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.